Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Basis of Loss Aversion
NCT06034158Unknown
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of levodopa + benserazide and propranolol (6 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Choices to invest or not in the investment task, Response times to invest or not in the investment task and 5 more. Status: unknown.
02
Drugs
levodopa + benserazidepropranolol
Beyond the preview
Go deeper on NCT06034158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034158.